ArticleScientific reports2026
Plasma aldosterone concentration and valvular heart disease in hypertensive patients: a large cross-sectional study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Prior research has demonstrated that plasma aldosterone concentration (PAC) is critically involved in cardiovascular disease (CVD). However, investigations specifically focusing on its association with valvular heart disease (VHD) remain limited. To address this gap in knowledge, this study aims to examine the relationship between PAC and VHD in hypertensive patients. The analysis included data from 35,622 hospitalized patients between January 2010 and February 2025. A multivariable logistic regression model was employed to evaluate the main relationship. To refine this relationship, restricted cubic spline (RCS) analysis was performed to investigate dose–response relationships and pinpoint possible inflection points. Additionally, subgroup analysis was performed to evaluate the data’ overall robustness. Logistic regression analysis showed a strong association of VHD with PAC levels. This association was further characterized using RCS, which illustrated a nonlinear dose-response relationship. Notably, the RCS model identified specific saturation points with threshold effects at PAC levels of 14.5 ng/dL, 14.2 ng/dL, and 15.0 ng/dL. The robustness of these findings was confirmed through consistent results in extensive subgroup and sensitivity analyses. This study offers the first proof of a substantial correlation between high PAC levels and VHD in hypertension patients. Large-scale, prospective investigations are necessary to validate these results and elucidate the causal link.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.